Topotecan for the treatment of recurrent and stage IVB cervical cancer

TA183 Cervical cancer (recurrent) - topotecan: review decision - December 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 57 KB)

Cervical cancer (recurrent) - topotecan: review proposal - September 2012 information

Appendix A: provisional matrix of stakeholders (PDF 64 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 343 KB)

Cervical cancer (recurrent) - topotecan: final appraisal determination information

Cervical cancer (recurrent) - topotecan: final appraisal determination (PDF 141 KB)

Response to consultee and commentator comments on the appraisal consultation document (PDF 110 KB)

Consultee and commentator comments on the ACD

Department of Health (PDF 7.9 KB)

Royal College of Nursing (PDF 21 KB)

GlaxoSmithKline (PDF 278 KB)

Cervical cancer (recurrent) - topotecan: appraisal consultation

Cervical cancer (recurrent) - topotecan: appraisal consultations document information

Cervical cancer (recurrent) - topotecan: evaluation report

Pre-meeting briefing (PDF 186 KB)

Cervical cancer (recurrent) - topotecan: evidence review group report (PDF 875 KB)

NICE clarification letter (PDF 474 KB)

Royal College of Nursing (PDF 31 KB)

Manufacturer submissions

Manufacturer response to clarification letter (PDF 395 KB)

GlaxoSmithKline (PDF 1.21 MB)

Expert written personal statements

Oakley (PDF 47 KB)

Pendleton (PDF 34 KB)

Symonds (PDF 67 KB)

Hirschowitz (PDF 35 KB)

Cervical cancer (recurrent) - topotecan: table of comments on draft scope (PDF 80 KB)

Cervical cancer (recurrent) - topotecan: table of comments on draft matrix (PDF 19 KB)

Cervical cancer (recurrent) - topotecan: matrix (PDF 32 KB)

Cervical cancer (recurrent) - topotecan: scope (PDF 27 KB)